These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 22954919)
1. [Multi-frequency low-dose intravenous iron on oxidative stress in maintenance hemodialysis patients]. Yin L; Chen X; Chen J; Cheng M; Peng Y; Yang L Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 37(8):844-8. PubMed ID: 22954919 [TBL] [Abstract][Full Text] [Related]
2. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study]. Li H; Wang SX Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093 [TBL] [Abstract][Full Text] [Related]
3. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Li H; Wang SX Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498 [TBL] [Abstract][Full Text] [Related]
4. Effect of frequency of intravenous iron administration on hemoglobin variability in maintenance hemodialysis patients. Wan L; Zhang D Int Urol Nephrol; 2018 Aug; 50(8):1511-1518. PubMed ID: 29946818 [TBL] [Abstract][Full Text] [Related]
5. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241 [TBL] [Abstract][Full Text] [Related]
6. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Li H; Wang SX Perit Dial Int; 2008; 28(2):149-54. PubMed ID: 18332450 [TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients. Saglam F; Cavdar C; Uysal S; Cavdar Z; Camsari T Ren Fail; 2007; 29(7):849-54. PubMed ID: 17994454 [TBL] [Abstract][Full Text] [Related]
8. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Attallah N; Osman-Malik Y; Frinak S; Besarab A Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942 [TBL] [Abstract][Full Text] [Related]
9. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146 [TBL] [Abstract][Full Text] [Related]
10. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Taylor JE; Peat N; Porter C; Morgan AG Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972 [TBL] [Abstract][Full Text] [Related]
11. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR; J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740 [TBL] [Abstract][Full Text] [Related]
12. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients. Nguyen TV Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125 [TBL] [Abstract][Full Text] [Related]
13. The efficiency of fractionated parenteral iron treatment in CAPD patients. Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661 [TBL] [Abstract][Full Text] [Related]
14. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients. Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750 [TBL] [Abstract][Full Text] [Related]
15. [Iron replacement in hemodialysis patients with a normal serum ferritin level]. Riedel MK; Morgenstern T Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of oxidative stress after repeated intravenous iron supplementation. Mimić-Oka J; Savić-Radojević A; Pljesa-Ercegovac M; Opacić M; Simić T; Dimković N; Simić DV Ren Fail; 2005; 27(3):345-51. PubMed ID: 15957553 [TBL] [Abstract][Full Text] [Related]
17. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients. Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014 [TBL] [Abstract][Full Text] [Related]
18. Intravenous ferric saccharate as an iron supplement in dialysis patients. Silverberg DS; Blum M; Peer G; Kaplan E; Iaina A Nephron; 1996; 72(3):413-7. PubMed ID: 8852489 [TBL] [Abstract][Full Text] [Related]
19. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Schaller G; Scheiber-Mojdehkar B; Wolzt M; Puttinger H; Mittermayer F; Hörl WH; Födinger M; Sunder-Plassmann G; Vychytil A Kidney Int; 2005 Dec; 68(6):2814-22. PubMed ID: 16316358 [TBL] [Abstract][Full Text] [Related]
20. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents. Malovrh M; Hojs N; Premru V Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]